Answers are grounded in this paper and cite their sources.
Background and Purpose Microsomal PGE synthase‐1 (mPGES‐1), the inducible synthase that catalyses the terminal step in PGE 2 biosynthesis, is of high interest as therapeutic target to treat inflammation. Inhibition of mPGES‐1 is suggested to be safer than traditional NSAIDs, and recent data demonstrate anti‐constrictive effects on vascular tone, indicating new therapeutic opportunities. However, there is a lack of potent mPGES‐1 inhibitors lacking interspecies differences for conducting in vivo studies in relevant preclinical disease models. Experimental Approach Potency was determined based on the reduction of PGE 2 formation in recombinant enzyme assays, cellular assay, human whole blood assay, and air pouch mouse model. Anti‐inflammatory properties were assessed by acute paw swelling in a paw oedema rat model. Effect on vascular tone was determined with human ex vivo wire myography. Key Results We report five new mPGES‐1 inhibitors (named 934, 117, 118, 322, and 323) that selectively inhibit recombinant human and rat mPGES‐1 with IC 50 values of 10–29 and 67–250 nM respectively. The compounds inhibited PGE 2 production in a cellular assay (IC 50 values 0.15–0.82 μM) and in a human whole blood assay (IC 50 values 3.3–8.7 μM). Moreover, the compounds blocked PGE 2 formation in an air pouch mouse model and reduced acute paw swelling in a paw oedema rat model. Human ex vivo wire myography analysis showed reduced adrenergic vasoconstriction after incubation with the compounds. Conclusion and Implications These mPGES‐1 inhibitors can be used as refined tools in further investigations of the role of mPGES‐1 in inflammation and microvascular disease.
No takes yet. Share an insight, caveat, or question.
Larsson et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: